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Abstract 22 
Trypanosoma brucei is the causative agent of human African trypanosomiasis (HAT), which is responsible for 23 
thousands of deaths every year. Current therapies are limited and there is an urgent need to develop new 24 
drugs. The anti-trypanosomal compound, 3-(oxazolo[4,5-b]pyridine-2-yl)anilide (OXPA), was initially 25 
identified in a phenotypic screen and subsequently optimized by  structure-activity directed medicinal 26 
chemistry.  It has been shown to be non-toxic and to be active against a number of trypanosomatid parasites. 27 
However, nothing is known about its mechanism of action. Here, we have utilized an untargeted 28 
metabolomics approach to investigate the biochemical effects and potential mode of action of this compound 29 
in T. brucei. Analysis of total metabolite extracts with HILIC-chromatography coupled to high resolution 30 
mass spectrometry revealed significant accumulation of ceramides in OXPA-treated T. brucei. To further 31 
understand drug-induced changes in lipid metabolism, a lipidomics method was developed which enables the 32 
measurement of hundreds of lipids with high throughput and precision. The application of this LC-MS based 33 
approach to cultured bloodstream-form T. brucei putatively identified over 500 lipids in the parasite 34 
including glycerophospholipids, sphingolipids and fatty acyls, and confirmed the OXPA-induced 35 
accumulation of ceramides. Labelling with BODIPY-ceramide further confirmed the ceramide accumulation 36 
following drug treatment. These findings clearly demonstrate perturbation of ceramide metabolism by OXPA 37 
and indicate that the sphingolipid pathway is a promising drug target in T. brucei.  38 
Keywords: Human African trypanosomiasis, Trypanosoma brucei, metabolomics, lipidomics, sphingolipid 39 
metabolism 40 
Page 3 of 26 
 
1. Introduction 41 
Human African trypanosomiasis (HAT), also referred to as sleeping sickness, is a vector-borne disease caused by 42 
the parasitic protozoa, Trypanosoma brucei (Brun et al. 2010). There are approximately 8,000 new cases of HAT 43 
annually, and the disease has a significant socioeconomic impact on communities (Simarro et al. 2011). HAT 44 
progresses through two stages; stage one occurs while the parasites proliferate within the haemolymphatic system 45 
and is usually associated with flu-like symptoms (Brun et al. 2010). Stage two occurs when the parasites cross the 46 
blood-brain barrier (BBB) and invade the central nervous system (CNS), leading to severe sleep disturbances, 47 
neurological symptoms and eventual death (Brun et al. 2010)..  48 
Currently available drugs for HAT suffer several drawbacks including resistance, toxicity, cost and/or requirement 49 
for hospitalization. Pentamidine and suramin are used to treat first-stage HAT caused by T.b. gambiense and T.b. 50 
rhodesiense subspecies, respectively. Neither of these compounds cross the BBB, rendering them ineffective against 51 
stage-two HAT (Voogd et al. 1993; de Koning 2001). The use of pentamidine can lead to the development of 52 
diabetes mellitus and nephrotoxicity (Nok 2003), while suramin has been linked to exfoliative dermatitis and renal 53 
failure (Voogd et al. 1993). Melarsoprol is used to treat patients with stage-two disease and is effective against both 54 
subspecies of T. brucei (Nok 2003; Seebeck and Maser 2009). However, melarsoprol is extremely toxic and high 55 
failure rates have been reported, though resistance has not yet been proven (Seebeck and Maser 2009). Eflornithine 56 
is a safer alternative for the treatment of second stage HAT (Seebeck and Maser 2009). However, it is not effective 57 
against T.b. rhodesiense infection (Seebeck and Maser 2009), and administration requires four intravenous infusions 58 
daily for 14 days and this is impractical in many rural African facilities (Priotto et al. 2009). Recently, nifurtimox 59 
has been introduced as a combination therapy with eflornithine, commonly denoted as NECT (Priotto et al. 2009). 60 
NECT has the advantage of a shorter and simplified treatment regimen making it the current first-line treatment for 61 
second-stage HAT caused by T.b. gambiense (Priotto et al. 2009). Few new drugs are in clinical development for 62 
HAT. These include the nitroheterocycle, fexinidazole which has progressed through phase 1 clinical trials (Drugs 63 
for Neglected Diseases 2012). The orally active benzoxaborole, SCYX-7158 was selected to enter phase 1 clinical 64 
trials in 2012, though the progression of the study has been delayed due to a longer than expected half-life of the 65 
drug in human plasma (DNDi 2015). Notwithstanding these developments, there is still a great need for new 66 
trypanocidal compounds, particularly for the CNS-resident second stage of this disease.  67 
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Recently, a high-throughput phenotypic screen of 87,000 compounds was undertaken against T.b. brucei leading to 68 
the identification of a novel lead inhibitor compound with a oxazolopyridine core (Sykes and Avery 2009; Sykes et 69 
al. 2012). Subsequent structure-activity relationship (SAR) investigations around this structure led to the 70 
development of 3-(oxazolo[4,5-b]pyridine-2-yl)anilide (OXPA; 1) as a potent inhibitor of T. brucei (Figure 1a) 71 
(Ferrins et al. 2013). The same chemical scaffold has been identified in independent phenotypic screening 72 
campaigns (Schenkman et al. 1991; Chatterjee 2014). We have shown that these compounds demonstrate potent 73 
activity against T.b. brucei (IC50: 0.17 µM) and T.b. rhodesiense (IC50: 0.07 µM), and also against other 74 
kinetoplastid parasites, Trypanosoma cruzi and Leishmania donovani, the causative agents of Chagas disease and 75 
visceral Leishmaniasis, respectively (Ferrins et al. 2013).  Minimal toxicity was observed in mammalian cells, 76 
suggesting that the oxazolopyridines are promising leads to discover new drugs for these neglected tropical diseases. 77 
The unique structure is unlike existing anti-kinetoplastid drugs and there is great interest in identifying the 78 
mechanism of action of this compound class to facilitate the optimisation of these broad spectrum anti-79 
kinetoplastids. 80 
Untargeted metabolomics combined with in vitro cell culture methods provide a promising tool for pharmacological 81 
research to determine mechanisms of drug action (Creek et al. 2012; Drexler et al. 2011). This approach has been 82 
validated in T. brucei, with specific perturbation of polyamines detected following treatment with eflornithine, an 83 
inhibitor of ornithine decarboxylase (Vincent et al. 2012). Drug-specific metabolic perturbations in T. brucei were 84 
also observed for nifurtimox (Vincent et al. 2012), pentamidine (Creek et al. 2013) and halogenated pyrimidines (Ali 85 
et al. 2013), and in T. cruzi for benznidazole (Trochine et al. 2014). This unbiased approach is ideally suited to the 86 
de novo discovery of drug mechanisms for novel trypanocidal compounds identified by high-throughput phenotypic 87 
screening (Creek et al. 2013).  88 
In this study, untargeted high resolution HILIC-MS metabolomics was applied to bloodstream-form T.b. brucei to 89 
elucidate the mechanism of action of OXPA. Treatment with this drug led to the selective accumulation of 90 
ceramides, which was confirmed using an optimized lipid profiling method and by measurement of the uptake and 91 
localization of fluorescently tagged ceramide. Collectively, these data suggest that sphingolipid metabolism is the 92 
major metabolic pathway targeted by OXPA.   93 
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2. Materials and Methods 94 
Parasite culturing for metabolic studies 95 
T.b. brucei bloodstream forms were cultured in Creeks minimal media (CMM) containing additional 100 µM 96 
hypoxanthine (Creek et al. 2013) and 5 mL cultures maintained in a 25-mL vented flask (Corning) at 37°C with 10% 97 
CO2. The cultures were grown to a maximum density of 2x106 cells ml-1 and sub-cultured every 2 or 3 days. Cell 98 
density was measured with a Neubauer hemocytometer. Growth curves were obtained in the presence of five times 99 
the IC50 concentration of OXPA (0.85 µM) to confirm that this is a sub-lethal concentration for 5h treatment (Creek 100 
et al. 2013).  101 
For metabolomics and lipidomics studies, a confluent cell culture was sub-cultured into fresh medium at 1 x 105 102 
cells ml-1, and OXPA (0.85 µM) or 4 μL DMSO (vehicle control) was added to flasks when cell density reached ~8 103 
x 105 cells ml-1. Cultures were further incubated for 5h (cell density reached 1x106 cells ml-1) and samples, including 104 
the controls, were quenched and extracted. Four independent biological replicates were prepared on separate days.  105 
Untargeted metabolomic analysis of drug-treated Trypanosoma brucei 106 
Parasites were metabolically quenched and extracted as previously described (Creek et al. 2013; Creek et al. 2011). 107 
A volume of 40 mL of cell culture was quenched by rapid cooling to 4°C in a dry ice ethanol bath. Cell pellets were 108 
obtained by centrifugation at 1,250 x g for 10min. The cell pellet was washed in 1 mL of phosphate-buffered-saline. 109 
The washed pellet, containing 4 x 107 cells was extracted with 100 μL chloroform:methanol:water (1:3:1 v/v) with 110 
periodic sonication and mixing for 1h at 4°C followed by centrifugation to remove the precipitate. The resulting 111 
metabolite solution was stored at -80°C until analysis by liquid chromatography-mass spectrometry with a Dionex 112 
Ultimate 3000 UHPLC system (Thermo Fisher scientific) and high resolution mass spectrometry (Q-Exactive 113 
Orbitrap; Thermo Fisher scientific). Chromatography was performed using a ZIC-pHILIC (Merck Sequant) column 114 
with ammonium carbonate and acetonitrile in the mobile phase (Creek et al. 2013). The instrument was operated in 115 
both positive and negative ion mode. Parameters for the HPLC and MS analysis were applied as previously 116 
described (Creek et al. 2011).  117 
Metabolomics data analysis 118 
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Metabolomics data analysis was performed with the freely available software packages mzMatch and IDEOM 119 
(http://mzmatch.sourceforge.net/ideom.php) as previously described (Trochine et al. 2014). Briefly, metabolite 120 
mixes containing 226 authentic metabolites were used to verify retention times and aid metabolite identification. 121 
Identification with those standards leads to a high confidence identification (MSI level 1) and these metabolites are 122 
highlighted yellow in the supplementary IDEOM file. Putative identification of all other metabolites was carried out 123 
by exact mass and predicted retention times from all metabolites from KEGG, Lipidmaps and MetaCyc databases 124 
(Creek et al. 2011). Metadata supporting the putative identification of each metabolite, and the associated metabolite 125 
identifiers are available in the supplementary IDEOM files which can be viewed in Excel. Relative quantification for 126 
the analysis is based on mean peak height and statistical analysis used unpaired Welch’s T-test. The data was not 127 
normalized, and signal reproducibility was ensured by the analysis of four spiked internal standards (CHAPS, TRIS, 128 
PIPES and CAPS), total ion current chromatograms (TIC) and median peak heights. Identified metabolites were 129 
filtered to ensure a maximum relative standard deviation (RSD) of 50% in the technical replicates of the pooled 130 
samples for the metabolomics study, and maximum RSD of 30% for the lipidomics study. Blank extraction buffer 131 
was analysed to identify and remove contaminating chemical species and sample carryover.  132 
Untargeted lipidomics analysis of drug treated Trypanosoma brucei 133 
Parasites were grown as described above, and lipid extraction was carried out as described in the metabolomics 134 
methods. Extracts were analyzed utilizing a C8 reversed-phase column (Ascentis Express C8, 5cm x2.1mm, 2.7μm, 135 
Supelco Anaytical) and Dionex Ultimate 3000 system (Thermo Fisher scientific) by applying the following settings: 136 
mobile phase A: 40% Isopropanol, 60% H2O, 2mM formic acid, 8mM ammonium formate. Mobile phase B: 2% 137 
H2O in isopropanol, 2mM formic acid, 8mM ammonium formate. The injector was washed before and after each 138 
injection with 3 mL 50:50 IPA:H2O. The column temperature was maintained at 40°C. Gradient: 0min 0%B 139 
(100%A) to 20%B in 1.5min linear, 1.5min to 7min linear to 28% B, 7min to 8min linear to 35%B, 8min to 24 min 140 
linear to 65%B, 24min to 25min linear to 100%B, 25min to 27min 100%B, 27min to 29min 100%A. Flow rate: 0-141 
24min 200μL/min, 24min-29min 500μL/min. MS analysis on the Q Exactive Orbitrap was carried out with the 142 
following settings: positive and negative mode combined at 140k resolution, AGC target 3e6, Maximum IT 200ms, 143 
Scan range 140 to 2000m/z. HESI source settings for flow rate 200μL/min: Heater temperature 158°C, S-lens RF 144 
level 50.00, Capillary temperature 300°C, spray voltage 3.50kV, sweep gas flow rate 2, aux gas flow rate 20, sheath 145 
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gas flow rate 50. HESI source settings for flow rate 500μL/min: Heater temperature 230°C, S-lens RF level 50.00, 146 
Capillary temperature 350°C, spray voltage 3.50kV, sweep gas flow rate 5, aux gas flow rate 35, sheath gas flow 147 
rate 45. Data analysis was carried out as described above for metabolomics. The retention time prediction model was 148 
disabled. For the pooled sample (sample including a fraction of all samples) data-dependent MSMS was performed 149 
using the following settings: Chromatographic peak with 15 seconds, loop count 5, normalized collision energy 150 
(NCE) 25%, positive and negative ionization ran separately, In source CID 0.0eV, Microscans 1, resolution 17.5k, 151 
AGC target 1e5, Maximum IT 50ms, scan range from 200 to 2000m/z, isolation window 4.0m/z, underfill ratio 1%, 152 
intensity threshold 2.0e4. The separation capability of the C8 reversed-phase column was validated by analysing 44 153 
lipid standards prior to the drug treated T.b. brucei extract.  154 
Accumulation of fluorescent ceramide 155 
T.b. brucei bloodstream forms (4 x 105 ml-1) were incubated with BODIPY-FL C5-ceramide (2.5 µM, Life 156 
Technologies Molecular Probes), and 2 µM OXPA was added to 10 mL of the culture and incubated for 5h and 24h. 157 
An equivalent amount of DMSO (vehicle) was added to the control flasks. After incubation, cells were concentrated 158 
by centrifugation at 700 x g, resuspended and fixed in 1 mL of 4% paraformaldehyde in PBS and incubated for 5 159 
minutes at 4°C. Cells were centrifuged for 6 minutes at 700 x g and washed with 1 mL of PBS. 1 µL of Rhodamine 160 
phalloidin (Sigma) solution and 0.4 µL of DAPI (Sigma) were added and incubated for 1 hour. Cells were 161 
centrifuged at 700 x g for 6 minutes and washed with 1 mL PBS and finally resuspended in 10 µL PBS for analysis 162 
by fluorescent microscopy (Leica TCS SP8 with a HC Plan APO 63x1.4 NA oil immersion objective, pictures 163 
captured in zoom 4). Wavelengths applied: DAPI Eex=405nm Eem=415nm-450nm, Phalloidin Eex=561nm 164 
Eem=570nm-620nm, BODIPY-FL-C5-Cer Eex=488nm Eem=475nm-540nm. Lipids were extracted and analysed as 165 
described above.  166 
Determination of IC50 by resazurin growth inhibition assay 167 
Compound activity against T.b. brucei was assessed in a resazurin viability assay as previously described by Sykes 168 
and Avery (Sykes and Avery 2009). Briefly, logarithmic phase T.b. brucei 427 bloodstream parasites at a 169 
concentration of 1200 cells/mL were added to 384-well microtiter plates (Greiner) in either 55µL of HMI-9 medium 170 
+ 10% FCS or 55µL of HMI-9 medium + 10% FCS supplemented with 1mM carnitine (Sigma). All assay plates 171 
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were incubated for 24 hours at 37°C/5% CO2. Serial drug concentrations of the test compound (OXPA) and 172 
carnitine were prepared in 100% DMSO and subsequently diluted 1:21 in DMEM media. 5 µL of this dilution was 173 
added to assay plates to give final drug concentrations ranging from 41.67 to 0.04 µM. Plates were incubated for 48 174 
hr at 37°C/5% CO2. 10 µL of 0.49mM of resazurin (Sigma Aldrich)  prepared in HMI-9 media +10% FCS was 175 
added to assay plates and plates incubated for a further 2 hr at 37°C/5% CO2 followed by 22 hr at room temperature. 176 
Assay plates were read at 535 nm excitation/590 nm emission on an Envision® multiplate reader (PerkinElmer, 177 
Massachusetts, USA). Data was analysed and IC50 values calculated using the software GraphPad Prism 5. 178 
Pentamidine, diminazene acetate and puromycin were included as controls and all experiments are a minimum of 179 
n=2.  180 
 181 
 182 
  183 
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Results  184 
Untargeted metabolomic analysis of drug treated T.b. brucei  185 
Metabolites were extracted from T.b. brucei bloodstream forms after 5h of incubation with either the test compound 186 
(OXPA) or DMSO and analysed with ZIC-pHILIC high resolution Orbitrap mass spectrometry. Signal extraction, 187 
artefact filtering and polarity merging of positive and negative ionization mode yielded a list of 475 putative 188 
metabolites which matched metabolite databases based on retention time and accurate mass. A list of putatively 189 
identified metabolites is supplied in Supporting Information File S1. According to the IDEOM software automated 190 
metabolite annotation, lipids were the most abundant metabolite class detected on this platform, representing 35% of 191 
all putatively identified metabolites, followed by metabolites of amino acid metabolism (19%). Putative metabolites 192 
that lack Lipidmaps or KEGG class/pathway annotations are listed as unmapped (23%) (Figure 1B). In order to 193 
detect metabolic changes induced by OXPA, metabolite abundances in untreated and treated cells were compared. 194 
Statistical analysis of the filtered data indicated that 11 (2.3%) putative metabolites showed a significant change ( 195 
= 0.05) by at least ±50% associated with treatment by OXPA (Figure 1C). Overall, 16 metabolites (3.4%) changed 196 
significantly (Table 1). Interestingly, most of these putative metabolites were ceramides, all of which accumulated in 197 
the presence of drug. Metabolites putatively assigned as riboflavin and N-acetyllactosamine also showed drug-198 
induced accumulation.  In contrast, levels of L-carnitine decreased in the presence of drug.  Levels of succinate, 6-199 
phospho-D-gluconate and O-acetylcarnitine were also depleted by at least 30% (Figure 1C).  200 
Untargeted lipidomics analysis of drug treated T.b. brucei 201 
Further studies were undertaken to confirm the impact of OXPA on ceramide levels using an untargeted lipidomics 202 
approach. In order to detect molecular targets of OXPA, parasite cultures were incubated with drug and the cellular 203 
lipidome measured after 5 hours of drug exposure. Lipids were extracted from bloodstream-form T.b. brucei and 204 
analyzed with a C8 reversed-phase column and high resolution mass spectra collected in both negative and positive 205 
ion mode. Several mobile phase conditions were compared and the isopropanol/ammonium formate buffer gradient 206 
described here provided optimal chromatographic separation and signal sensitivity, consistent with the findings of 207 
other recent lipidomics studies (Yamada et al. 2013; Hu et al. 2008; Chai 2014). Signal extraction, artefact filtering 208 
and polarity merging of positive and negative ion mode yielded a list of 517 lipids which matched metabolite 209 
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databases based on accurate mass and retention times where available. A list of putatively identified metabolites is 210 
supplied in Supporting Information File S2.  Major lipid classes detected by these analyses were molecular species 211 
of phosphatidylcholine (PC: 19%), phosphatidylethanolamine (PE: 17%), fatty acids (FA: 11%), phosphatidylserine 212 
(PS: 11%), phosphatidylinositol (PI: 6%), sphingomyelin (SM: 6%), neutral glycerolipid (GL: 6%), ceramide (Cer: 213 
5%), glycerophosphoglycerol (PG: 4%), sterol (ST: 4%), ethanolamine phosphorylceramides (EPC: 2%), 214 
glycerophosphates (PA: 2%), sphingoid bases (1%)  and lipid metabolism intermediates (2%). Additional lipids 215 
included prenols, flavonoids, gangliosides, phosphatidylinositol phosphates, phosphatidylethanolamine phosphates, 216 
glycerols and other hydrophobic metabolites which may be trypanosome-derived or may have been acquired from 217 
the serum in the growth medium (Figure 2A).  Our new lipidomics method shows low relative standard derivations 218 
(RSD < 30%) for over 90% of detected lipids (Figure 2B), indicating excellent reproducibility and clear separation 219 
of authentic lipid standards (Figure 2C) and biological extracts (Figure 2D/E). Statistical analysis of automatically 220 
processed data indicated that 13 lipids (2.5% of all putative lipids) showed a significant change (α <0.05) induced by 221 
the treatment with OXPA by at least ±30% (Table 2) – a lower threshold was used for the lipidomic study due to the 222 
superior reproducibility demonstrated for this method (Figure 2B). Consistent with the HILIC-based metabolomics 223 
experiment, OXPA primarily impacted on the levels of ceramides (85% of significantly perturbed lipids), with a 224 
total of 11 out of 28 ceramide species exhibiting significant increases (Figure 3). Data-dependent MS/MS allowed 225 
confirmation of the identity of the significantly perturbed ceramides (for the 8 ceramides where MS/MS spectra 226 
were available) by the signature ion at m/z 264 (or 266 for dihydroceramides; or 238 for C16-dihydroceramide) 227 
(Supporting Information, File S3). The corresponding SM species showed no significant changes except for the SM 228 
derived from Cer(32:0) and Cer(34:0), which showed a significant increase (20%) according to an unpaired Welch’s 229 
t-test (α=0.05) (data in supplementary file 2). Eleven corresponding EPC species were detected with no significant 230 
perturbation caused by OXPA treatment. No IPC species were detected in any samples.  231 
 232 
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Localisation and metabolism of fluorescent ceramide 233 
Bloodstream-form T.b. brucei were incubated with BODIPY-C5 ceramide to verify ceramide accumulation caused 234 
by incubation with OXPA, as observed in the metabolomics and lipidomics analyses. Parasites were incubated in the 235 
presence of BODIPY-FL-C5-cer for 5 h and 24 h with OXPA or DMSO control, and parasites were co-stained with 236 
Phalloidin and DAPI to monitor morphological changes to T.b. brucei due to treatment. Untreated (DMSO control 237 
5h, 24h) T.b. brucei show a long slender form and the nuclear and mitochondrial DNA (kinetoplast) localization are 238 
consistent with healthy parasites (Matthews 2005). Treatment with OXPA for 5h causes swelling of the parasite and 239 
a generally more rounded morphology. By 24h, BODIPY ceramide accumulation was evident adjacent to the 240 
nucleus, consistent with staining of the Golgi apparatus where conversion of ceramide to more complex lipids (IPC, 241 
SM, EPC) occurs (Sutterwala et al. 2008; Fridberg et al. 2008; Sutterwala et al. 2007). A 24h treatment caused 242 
further swelling and rounding of the parasite compared to the controls and 5h treatment (Figure 4). Lipids were 243 
extracted from 24h treated bloodstream-form T.b. brucei and analyzed by the C8 reversed phase column and high 244 
resolution MS in order to confirm BODIPY-ceramide accumulation. Significant accumulation of BODIPY-ceramide 245 
was observed (54% increase) when parasites were treated with OXPA for 24h.  Interestingly, the corresponding 246 
BODIPY-sphingomyelin (C39H66BF2N4O6P) and BODIPY-EPC (C36H60BF2N4O6P) species were also detected at 247 
significantly higher abundance in the drug-treated cells (Figure 5), suggesting that accumulated BODIPY-ceramide 248 
is further processed and these steps are not inhibited by OXPA.  249 
 250 
Discussion 251 
In this study we have investigated the mode of action of OXPA, a lead anti-trypanosomatid drug candidate, using 252 
two complementary metabolomic profiling approaches involving HILIC and C8 reversed phase chromatography 253 
coupled to high resolution mass spectrometry. This study extends previous metabolic studies on trypanosomes that 254 
utilized the HILIC chromatography mass spectrometry platform (Vincent et al. 2012; Silva et al. 2011; t'Kindt et al. 255 
; Kamleh et al. 2008; Trochine et al. 2014). Overall 475 metabolites were detected in the HILIC study, and the 256 
concentrations of 16 of those metabolites changed significantly when treated with the novel anti-trypanosomal 257 
compound OXPA. Strikingly, six of the significantly perturbed metabolites were ceramides, all of which 258 
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accumulated by at least 50% due to treatment. Ceramides contain a sphingolipid base and amide-linked fatty acid 259 
and can function as a key player in cell signaling as well as a precursor for complex sphingolipids (Futerman and 260 
Hannun 2004). In order to analyze effects of OXPA on the lipidome in more detail, we developed a new LC-MS 261 
method that employed a C8 reversed-phase chromatographic separation coupled to high resolution Orbitrap MS. 262 
This method can be used to screen total cellular lipids within 30 minutes in positive and negative ion mode with a 263 
mass resolution of 140k. Analysis of drug treated bloodstream-form T.b. brucei with this lipidomic method shows 264 
excellent separation for nonpolar metabolites with low RSD’s and putative identification of 517 lipids. 265 
Glycerophospholipids were the most abundant lipid classes observed, which represented over 50 % of all detected 266 
lipids. All major phospholipid classes were found in bloodstream-form T.b. brucei in agreement with previous 267 
reports (Patnaik et al. 1993). Increased molecular species complexity was observed in the phosphatidylserines than 268 
reported in a previous study (Richmond et al. 2010), likely due to the different selectivity of the analytical platforms.  269 
Analysis of the lipidome of bloodstream-form T.b. brucei after 5 hours treatment with 0.85 µM OXPA, confirmed 270 
that all of the ceramides detected in the untargeted HILIC metabolite analysis were increased in the presence of 271 
OXPA. Overall, 11 ceramides showed a significant change (by at least 30%) supporting the notion that OXPA 272 
directly impacts the ceramide metabolism and/or intracellular transport in the parasite. Furthermore, our imaging 273 
study with BODIPY-C5-Cer also clearly showed accumulation of ceramides in the treated parasites, most likely in 274 
the Golgi apparatus where SMs and EPCs are synthesized (Sutterwala et al. 2008), confirming our findings from 275 
metabolomics and lipidomics analyses. 276 
Ceramide accumulation induced by OXPA could, in principle, arise as a result of decreased ceramide degradation or 277 
decreased conversion of ceramide to higher order sphingolipids. T. brucei lacks a known pathway for ceramide 278 
catabolism (consistent with the finding that neither sphingosine nor sphingosine 1-phosphate were detected in our 279 
analyses), suggesting that accumulation is due to altered metabolism. In T. brucei, ceramide is converted to complex 280 
sphingolipids such as SM, IPC and EPC, by the transfer of phosphocholine, phosphoinositol or 281 
phosphoethanolamine to ceramides, respectively (Becker and Lester 1980; Bromley et al. 2003; Denny et al. 2006; 282 
Sutterwala et al. 2008). Consistent with previous studies (Sutterwala et al. 2008; Sutterwala et al. 2007) we show 283 
that bloodstream forms predominantly synthesize EPCs and SMs, but not IPCs. Furthermore, BODIPY-labelled 284 
ceramide was efficiently incorporated into both SM and EPC. T. brucei possess a family of sphingolipid synthases, 285 
Page 13 of 26 
 
encoded by TbSLS1-4, that catalyse the synthesis of complex sphingolipids, and knockdown of these enzymes has 286 
been shown to lead to ceramide accumulation (Sutterwala et al. 2008; Serricchio and Butikofer 2011; Mina et al. 287 
2009). However, the increased production of BODIPY-labelled SM and EPC in treated cells suggests that inhibition 288 
of sphingolipid synthase is not the primary mechanism of ceramide accumulation observed for OXPA. Interactions 289 
with alternative molecular targets in the ceramide uptake or sphingolipid metabolism pathways may be responsible 290 
for the observed ceramide accumulation. Alternative mechanisms, such as the activation of the endogenous neutral 291 
sphingomyelinase that degrades exogenous sphingolipids to ceramide (Young and Smith 2010) or the upregulation 292 
of de novo biosynthesis are unlikely, as up-regulation was also observed when exogenous BODIPY-Cer was added 293 
to parasite cultures. On the other hand, our data are consistent with a partial defect in the post-Golgi transport of 294 
sphingolipids, leading to an accumulation of ceramide and freshly synthesized complex sphingolipids. Future work 295 
will delineate the precise molecular target(s) involved in this mechanism.  296 
The HILIC analysis of polar metabolites indicated that OXPA also led to depletion of the carnitines, O-297 
acetylcarnitine (C9H17NO4) and L-carnitine (C7H15NO3). The potential role of carnitine acetylation/acylation in 298 
bloodstream-form T. brucei has not been fully defined. Unlike the insect stage, the mammalian infective 299 
bloodstream form is completely dependent on glycolysis for ATP production (Gilbert and Klein 1984). In other 300 
eukaryotes, conversion of L-carnitine to O-acetyl-carnitine by carnitine acetyl transferase (CAT) (Friedman and 301 
Fraenkel 1955) results in depletion of acetyl-CoA and stimulation of pyruvate kinase activity directly or indirectly 302 
(Gilbert and Klein 1984). A decrease in L-carnitine levels in T. brucei could lead to a decrease of O-acetylcarnitine 303 
synthesis, with a concomitant increase in acetyl-CoA production and partial inhibition of pyruvate kinase activity, 304 
with subsequent effects on ATP synthesis and parasite survival. African trypanosomes cannot synthesize L-carnitine 305 
but scavenge carnitine from the medium/host via an active transporter, which has been reported as a validated drug 306 
target (Gilbert et al. 1983). These findings raised the possibility that carnitine uptake may be inhibited by OXPA. 307 
Interestingly, the glycolytic metabolite 3-phospho-D-glycerate (C3H7O7P) demonstrates a decrease in abundance by 308 
at least 30% following treatment, consistent with a down-regulation of glycolysis. In order to test the hypothesis of 309 
carnitine uptake inhibition, the in vitro activity of OXPA was measured in presence of high extracellular levels of L-310 
carnitine (1 mM). No inhibition of activity was observed, and surprisingly our results indicate a two-fold decrease in 311 
IC50 in the presence of excess L-carnitine (Supporting Information File S4). A similar trend was also observed with 312 
pentamidine, indicating some non-specific mild synergistic effect due to the very high concentration of L-carnitine. 313 
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Overall, the data clearly rejects the hypothesis that excess carnitine would inhibit the activity of OXPA, and suggests 314 
that inhibition of carnitine uptake is not the primary mechanism of action of this compound. 315 
The untargeted metabolomics analysis revealed few additional statistically significant perturbations to specific 316 
metabolites which may play a role in the activity, and/or potential toxicity of the oxazolopyridines. The metabolite 317 
annotated as N-acetyllactosamine (C14H25NO11) increased in abundance by 60%, and depletion of succinate by 33% 318 
and 6-phospho-D-gluconate by 56%, may indicate some impact on the pathways of glycoconjugate salvage, central 319 
carbon metabolism and NAD(P)+/NAD(P)H balance (Hanau et al. 2004; Fairlamb and Opperdoes 1986; Tielens and 320 
Van Hellemond 1998; Besteiro et al. 2002). The mechanism of riboflavin accumulation is uncertain, and further 321 
investigations are necessary to confirm the relevance of these changes that were isolated to individual metabolites 322 
within diverse pathways. The perturbations to these individual metabolites may be relevant to a thorough 323 
understanding of the systems pharmacology of this drug class, but are unlikely to represent the trypanocidal target of 324 
OXPA, as other metabolites in these pathways were unaffected. In contrast, the reproducible accumulation observed 325 
for a large proportion of the observed ceramides suggests that sphingolipid metabolism is the primary target for the 326 
anti-trypanosomal activity of OXPA.  It is important to note that most detected metabolites were not significantly 327 
impacted by treatment with OXPA. In particular, polyamine and sterol pathway metabolites were not perturbed, 328 
suggesting that this compound does not share targets with other common anti-trypanosomal drugs, such as ornithine 329 
decarboxylase (Vincent et al. 2012) and sterol 14-demethylase (CYP51) (Choi et al. 2014). To confirm this, 330 
inhibition of CYP51 inhibition was measured in vitro using the purified enzyme, and no activity was observed for 331 
OXPA (IC50 > 10µM), whereas the known CYP51 inhibitor pozaconazole demonstrated an enzyme inhibition IC50 332 
of 40 nM. The metabolic profile observed for OXPA was unique compared to those observed for several other anti-333 
trypanosomal compounds tested using the same metabolomics methodology (Ali et al. 2013; Creek et al. 2013; 334 
Trochine et al. 2014; Vincent et al. 2012), confirming that the perturbations observed here are specific to this 335 
compound class, and do not represent a non-specific cell death phenotype. 336 
 337 
Metabolomics and lipidomics enabled an unbiased assessment of the biochemical actions of OXPA in T. brucei. 338 
Mass spectrometry based metabolomics with our optimised C8 reversed-phase lipidomics method and fluorescence 339 
microscopy clearly demonstrated that the oxazolopyridine anti-trypanosomal compound (OXPA) caused significant 340 
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accumulation of ceramides, indicating a mechanism of action targeting sphingolipid metabolism or trafficking. 341 
These findings provide chemical validation of sphingolipid metabolism and/or trafficking as an attractive pathway 342 
for future drug discovery in T. brucei. Specifically, this is the first description of the unique impact of 343 
oxazolopyridines on sphingolipid metabolism in T. brucei, providing the basis for future studies investigating the 344 
precise molecular target(s) and potential mechanism(s) of resistance for OXPA and related drug candidates. The 345 
mechanistic information described here will allow targeted analysis of the biochemical impact of oxazolopyridines 346 
in pre-clinical and clinical studies, thus facilitating the development of oxazolopyridines as drug candidates for HAT 347 
and other trypanosomatid diseases. 348 
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Figure Legends 519 
Figure 1: A: Structure of the novel anti-trypanosomal 3-(oxazolo[4,5-b]pyridine-2-yl)anilide (OXPA; 1). B: 520 
Distribution of total metabolites putatively identified in treated and untreated bloodstream-form T.b. brucei. 521 
Heatmap depicts relative metabolite abundance of putative metabolites from each of the metabolite classes. C: Four 522 
replicates of untreated sample T: Four replicates treated with 0.85 µM OXPA for 5 hours. A total of 475 metabolites 523 
were detected. C: Metabolites displaying significant differences between control and 0.85 µM OXPA-treated 524 
T.b. brucei samples by at least 50%. All metabolites displayed were significantly perturbed according to unpaired 525 
Welch’s T-test ( = 0.05) and fold change >1.5, <0.5 (n = 4). Metabolites categorized according to KEGG and 526 
Lipidmaps annotations. Succinate, 3-Phospho-D-glycerate and O-acetylcarnitine changed by less than 50% but are 527 
significantly perturbed metabolites from associated pathways. 528 
 529 
Figure 2: A:  Distribution of total lipids in bloodstream-form T.b. brucei sample. The pie chart depicts the 530 
number of putatively identified lipids from each lipid class, classified according to KEGG and Lipidmaps. A total of 531 
517 lipids were analysed. B: Relative standard deviation (RSD) for all lipids detected in C8 reversed phase 532 
analysis from bloodstream-form T.b. brucei. Lipids with RSD <0.3: 92.5%, RSD <0.5: 97.5%. C: Separation of 533 
lipid standards by C8 reversed phase chromatography, RA: relative abundance, RT: retention time,  1: 534 
C14H25NO6:[Pimelylcarnitine], 2: C26H52NO7P [PC (18:1)],  3: C34H66NO10P [PS (14:0/14:0)], 4:  C36H72NO8P [PC 535 
(14:0/14:0)],  5: C41H81N2O6P [SM(d18:1/18:1(9Z))], 6: C44H84NO8P [PC (18:1/18:1)], 7: C45H91N2O6P 536 
[SM(d18:1/22:0)], 8: C49H99N2O6P [SM(d18:1/26:0)], 9: C42H83NO3 [Cer(d18:1/24:0)], 10: C55H96O6 537 
[TG(16:0/16:0/20:3)]. D: Separation of T.b. brucei lipids by C8 reversed phase chromatography and mass 538 
spectrometry. E: Separation of T.b. brucei sphingolipids by C8 reversed phase chromatography and mass 539 
spectrometry. Each dot represents a detected lipid species, coloured by lipid class. The size of each spot is 540 
proportional to the total number of double-bonds in the acyl chains. The general relationship between mass and 541 
retention time is observed within each class, with allowance for earlier elution of highly unsaturated species, and 542 
later elution of ether-linked phospholipids. GL: neutral glycerolipids, PC: phosphotidylcholines, PE: 543 
phosphatidylethanolamines, PI: phosphatidylinositols, PG: phosphatidylglycerols, PS: phosphatidylserines, PA: 544 
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phosphatidic acids, ST: sterols, SE: sterol esters, FA: fatty acyls, SB: sphingoid bases, SM: sphingomyelins, EPC: 545 
ethanolamine phosphorylceramides, Cer: ceramides, Gan: Gangliosides, (-O): indicates ether-lipids, (OH): indicates 546 
hydroxylated lipids.  547 
 548 
Figure 3: A: The number of significantly perturbed lipids in each class after treatment with OXPA, expressed 549 
as a percentage of the total number of identified lipids per class. Significance determined by unpaired Welch’s 550 
T-test ( = 0.05). Classification according to KEGG and Lipidmaps. B: Volcano plot demonstrating that the most 551 
significantly perturbed lipids were ceramides. X-axis represents the relative abundance of each lipid in OXPA-552 
treated parasites relative to untreated controls. Y-axis indicates significance based unpaired Welch’s t-test (n=4). 553 
Ceramides (red), ethanolamine phosphorylceramides (green) and sphingomyelins (blue) are shown in coloured 554 
spots. Black circles represent all other detected lipids. C: Relative intensity of all detected ceramides in T.b. 555 
brucei treated with OXPA (dark columns) and untreated parasites (light columns). Ceramide abundance is 556 
shown as mean of LCMS peak intensity ± standard deviation (n=4) with significant differences (*) determined by 557 
Welch’s T-test ( = 0.05). Note that four scales are included to allow for the three orders of dynamic range in 558 
detected ceramide levels. 559 
 560 
Figure 4: Ceramide accumulation in bloodstream-form T.b. brucei following treatment with OXPA. T.b. 561 
brucei bloodstream forms were incubated with BODIPY-FL-C5-ceramide in the presence or absence of OXPA and 562 
visualised by fluorescent microscopy. C: 5 hours and 24 hours untreated, T: treated for 5 hours and 24 hours with 563 
OXPA (two replicates shown). All cells were incubated with BODIPY-FL-C5-ceramide (green) and co-stained with 564 
DAPI (blue) and Rhodamine phalloidin (red). k: kinetoplast, n: nucleus, BF: bright field 565 
 566 
Figure 5: BODIPY-C5-FL-Ceramide accumulation after 24h treatment with OXPA. A: LC-MS peak intensity 567 
(mean ± standard deviation) for BODIPY-ceramide (C34H54BF2N3O3), B: BODIPY-Sphingomyelin 568 
(C39H66BF2N4O6P) and C: BODIPY-EPC (C36H60BF2N4O6P) from T.b. brucei incubated for 24h with BODIPY-C5-569 
FL-Ceramide and either OXPA or control (untreated). All comparisons show significant difference (*) according to 570 
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Welch’s unpaired t-test (α=0.05) (n = 2-3). D: Acquired mass spectra for BODIPY-ceramide E: BODIPY-571 
Sphingomyelin and F: BODIPY-EPC. Negative ion spectra demonstrating the accurate mass and boron-specific 572 
isotopic pattern.  573 
  574 
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Tables 575 
Table 1: Metabolites with significant changes arising after 0.85 µM OXPA treatment of bloodstream-form 576 
T.b.  brucei 577 
        Mass 
error 
[ppm] 
          
Proposed metabolite 
Proposed 
formula 
m/z 
RT 
[min] 
Class 
Mean 
Intensity 
Fold 
change 
p-
Value 
RSD 
[%] 
 Cer(36:2)   C36H69NO3  563.52745  3.80  -0.52  Ceramide  3.00E+06  2.08 0.046  32 
 Cer(33:1)   C33H65NO3  523.49629  3.87  -0.29  Ceramide  4.39E+06  1.95  0.0111  20 
 Cer(34:1)   C34H67NO3  537.51205  3.84  -0.08  Ceramide  7.03E+07  1.89  0.0043  16 
 Cer(35:1)   C35H69NO3  551.52754  3.81  -0.37  Ceramide  9.96E+06  1.76  0.0295  22 
 Cer((34:0(OH))  C34H69NO4  555.52259  3.90  -0.12  Ceramide   2.67E+06  1.88  0.0261  25 
 Cer((36:0(OH))  C34H69NO4  583.55371  3.95  -0.42  Ceramide   2.93E+05  1.92  0.0412  30 
 3,4-Dihydroxy 
phenylethyleneglycol 
 C
8
H
10
O
4
  170.05791  13.29  -0.01 
 Amino Acid 
Metabolism 
 1.41E+05  1.32  0.0140  10 
 CMP  C9H14N3O8P  323.052  15.83  0.48 
 Nucleotide 
Metabolism 
 1.74E+05  1.45  0.0339  17 
 3-Phospho-D-glycerate  C3H7O7P  185.99295  16.93  0.05 
 Carbohydrate 
Metabolism 
 1.31E+07  0.67  0.0257  12 
 6-Phospho-D-
gluconate 
 C
6
H
13
O
10
P  276.02463  17.64  -0.02 
 Carbohydrate 
Metabolism 
 3.48E+04  0.44  0.0452  31 
 D-Glycerate  C3H6O4  106.02659  11.78  -0.27 
 Carbohydrate 
Metabolism 
 7.28E+06  0.78  0.0330  15 
 Imidazole lactate  C6H8N2O3  156.05349  11.25  0.01 
 Amino Acid 
Metabolism 
 1.74E+06  0.72  0.0300  12 
 L-carnitine  C7H15NO3  161.10514  13.13  -0.31 
 Amino Acid 
Metabolism 
 1.24E+08  0.50  0.0092  7 
 N-acetyllactosamine  C14H25NO11  383.143  13.31  0.25 
Glycoconjugate 
Metabolism 
 1.65E+06  1.6  0.0485  11 
 O-acetylcarnitine  C9H17NO4  203.11577  10.91  0.05 
 Amino Acid 
Metabolism 
 5.33E+07  0.42  0.0363  35 
 Primin  C12H16O3  208.1098  3.86  -0.71  unmapped  1.34E+05  0.76  0.0088  7 
 Riboflavin  C17H20N4O6  376.138  8.54  0.08 
 Metabolism of 
Cofactors and 
Vitamins 
 2.01E+05  1.72  0.0226  22 
 Succinate  C4H6O4  118.02665  15.04  0.37 
 Carbohydrate 
Metabolism 
 3.93E+07  0.67  0.0269  22 
Ions detected from 0.85 µM OXPA-treated parasites, retrieved from filtered raw metabolomics data and IDEOM 578 
assisted identification with HILIC chromatography. Proposed metabolite: proposed metabolite for each ion. 579 
Proposed formula: Formulas obtained using m/z data with IDEOM. m/z: detected mass/charge ratio corrected for 580 
the mass of one proton RT: retention time. Mass error (ppm): [(m/z(observed)-581 
m/z(theoretical))/m/z(theoretical)]*1E+6. Mean intensity: mean peak intensity value for each ion in the treated 582 
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samples. Fold change: relative abundance of mean of corresponding ions in treated samples compared to the mean 583 
of controls. P-value: value for unpaired Welch’s t-test. RSD: relative standard derivation of treated samples. 584 
Table 2: Lipids with significant changes (± 30%) arising after OXPA treatment of bloodstream-form T.b. 585 
brucei 586 
        
Mass error 
[ppm] 
          
Proposed lipid 
Proposed 
formula 
m/z 
RT 
[min] 
Class 
Mean 
intensity 
Fold 
change 
p-Value 
RSD 
[%] 
 Cer(32:0)  C32H65NO3  511.5 11.92  3.96E-05  Ceramide  5.56E+05 1.53  0.005  8 
 Cer(36:1)   C36H71NO3  565.54 14.08  0.27  Ceramide  2.04E+07 1.44  0.001  7 
 Cer(33:1) *  C33H65NO3  523.5 12.03  0.14  Ceramide  6.25E+06 1.41  0.0003  3 
 Cer(32:1)  C32H63NO3  509.48 11.41  -0.04  Ceramide  1.58E+06 1.37  0.015  10 
 Cer(34:0)  C34H69NO3  539.53 13.24  0.01  Ceramide  1.78E+07 1.36  0.005  7 
 Cer(35:0)  C35H71NO3  553.54 13.97  0.31  Ceramide  2.52E+06 1.35  0.020  5 
 Cer(34:1) *  C34H67NO3  537.51 12.68  0.09  Ceramide  1.32E+08 1.35  0.002  7 
 Cer(35:1) *  C35H69NO3  551.53 13.36  -0.17  Ceramide  1.25E+07 1.33  0.0002  3 
 Cer(35:0(OH))  C35H71NO4  569.54 12.67  -0.21  Ceramide  1.18E+06 1.32  0.007  5 
 Cer(36:1(OH))  C36H71NO4  581.54 12.51  -0.12  Ceramide  3.26E+05 1.32  0.027  20 
PC(18:2)  C26H52NO6P  505.35 4.46  0.81 Phosphatidylcholine  2.83E+05 0.64  0.016  11 
FA(oxo11:0) C11H20O3  200.14 1.32  0.85 Fatty Acyls  2.10E+05 1.49  0.044  13 
Ions detected from OXPA-treated parasites, retrieved from filtered raw lipidomics data and IDEOM assisted 587 
identification from reversed-phase chromatography. Proposed lipid: proposed lipid for each ion. Proposed 588 
formula: Formulas predicated using m/z data with IDEOM. m/z: detected mass/charge ratio corrected for the mass 589 
of one proton RT: retention time. Mass error (ppm): [(m/z(observed)-m/z(exact))/m/z(exact)]*1E+6. Mean 590 
intensity: mean peak intensity value for each ion of the treated sample. Fold change: change in mean abundance of 591 
corresponding ion in treated samples compared to the control. P-Value: value for unpaired Welch’s T-test with a 592 
threshold of p<0.05. RSD: relative standard derivation. *lipids that were also detected in the HILIC analysis of drug 593 
treated bloodstream T.b. brucei.  594 
